Showing 2341-2350 of 5268 results for "".
- Extreme Weather and Skin Disease: What’s the Connection?https://practicaldermatology.com/news/extreme-weather-and-skin-disease-whats-the-connection/2461395/As floods, wildfires, and extreme heat events increase in frequency and severity, they pose a significant threat to global dermatological health, as many skin diseases are climate sensitive, according to The Journal of Climate Change and Health. “We wanted to provide dermatol
- U.S FDA Clears EndyMed’s Hair Removal Devicehttps://practicaldermatology.com/news/fda-clears-endymeds-hair-removal-device/2461393/The US Food and Drug Administration has cleared Endymed Ltd’s Pure Laser hair removal device for the marketing and sales. The Pure Laser was developed in the Company's labs by its subsidiary Endymed Medical Ltd. The Company intends to commence marketing in the US th
- Study: Galderma's RelabotulinumtoxinA Earns High Marks from Patientshttps://practicaldermatology.com/news/study-galdermas-relabotulinumtoxina-earns-high-marks-from-patients/2461377/Galderma's investigational ready-to-use liquid botulinum toxin RelabotulinumtoxinA scored high patient satisfaction and psychological well-being ratings for the treatment of glabellar lines and lateral canthal lines in addition to previously reported safety and efficacy, according to pre
- Crown's Skinpen Scores New Indications in the EU and UKhttps://practicaldermatology.com/news/crowns-skinpen-scores-new-indications-in-the-eu-and-uk/2461375/Crown Aesthetics’ SkinPen Precision scored three new approved indications in the EU and UK. The new&
- NEA Introduces New “Focus on Eczema” Campaign for Eczema Awareness Month 2022https://practicaldermatology.com/news/nea-introduces-new-focus-on-eczema-campaign/2461367/The National Eczema Association (NEA) is rolling out its annual
- Galderma, NBCF Partner to Launch Campaign Elevating Skin Stories of Breast Cancer Survivorshttps://practicaldermatology.com/news/galderma-nbcf-partner-to-launch-campaign-elevating-skin-stories-of-breast-cancer-survivors/2461366/Galderma is continuing its partnership with National Breast Cancer Foundation Inc. (NBCF) with a new campaign that elevates the skin stories of breast cancer survivors. Galderma is featuring the personal stories and treatment journeys of breast cancer survivors who received Re
- Evommune Initiates Phase 2a Proof-of-Concept Clinical Trial of EVO101 in ADhttps://practicaldermatology.com/news/evommune-initiates-phase-2a-proof-of-concept-clinical-trial-of-evo101-in-ad/2461362/Evommune, Inc. enrolled the first patient in a Phase 2a proof-of-concept clinical trial evaluating EVO101, a novel small molecule inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK4), in patients with atopic dermatitis (AD). The Phase 2a trial is a randomized, double-bl
- Two New Studies Highlight the Efficacy and Safety Profile of Revance's DAXXIFYhttps://practicaldermatology.com/news/two-new-studies-highlights-the-efficacy-and-safety-profile-of-daxxify/2461360/Glabellar injection of DAXXIFY show a positive effect on eyebrow position and a high response rate and duration of effect ≥24 weeks across all age and race subgroups, according to two new studies in the Aesthetic Surgery Journal. “The newly released pu
- Investigational Cannabinoid Receptor Agonist Proves Safe and Effective in Amyopathic Dermatomyositishttps://practicaldermatology.com/news/investigational-cannabinoid-receptor-agonist-proves-safe-and-effective-in-amyopathic-dermatomyositis/2461357/Lenabasum, a cannabinoid receptor agonist, is an effective and safe treatment for amyopathic dermatomyositis, a new study in the Journal of Investigative Dermatology suggests. This phase 2 trial, the
- EMA Accepts Marketing Authorization Applications for UCB's Bimekizumab in Psoriatic Arthritis and Axial Spondyloarthritishttps://practicaldermatology.com/news/ema-accepts-marketing-authorization-applications-for-ucbs-bimekizumab-in-psoriatic-arthritis-and-axial-spondyloarthritis/2461354/The European Medicines Agency (EMA) has accepted for regulatory review the two marketing authorization applications for UCB's bimekizumab for the treatment of adult patients with active psoriatic arthritis (PsA), and adult patients with active axial spondyloarthritis (axSpA). &ldquo